As an intriguing outcome of these investigations, the S1P1 antagonist FTY720 has been shown to elicit strong anti-angiogenic effects and to inhibit breast cancer growth both in vitro and in vivo [144,145,146]. Here, S1PR1 is linked to breast carcinoma.